Obstacles to mineralocorticoid receptor antagonists in a community-based heart failure population.

Abstract:

AIM:Previous studies and national assessments indicate an undertreatment of mineralocorticoid receptor antagonists (MRA) in heart failure with reduced ejection fraction (HFrEF). This study aimed to investigate why MRA is not used to full extent. METHODS:A complete community-based heart failure population was studied. Several variables were collected, and medical records were scrutinized to identify reasons for not prescribing MRA. RESULTS:Of 2029 patients, 812 had EF ≤40%. Five hundred and fifty-three patients (68%) tried MRA at some point but 184 of these (33%) discontinued therapy. There were 259 patients that never tried MRA with 177 with a listed explanation or contraindication. Eighty-two patients, 10% of the total HFrEF population, had no clear contraindications. They were older and had less HF hospitalizations compared to patients on MRA (P < 0.05) and 32% did not have any follow-up at the cardiology clinic. Contraindications to MRA were renal dysfunction (93 patients), hypotension (28 patients), and hyperkalemia (25 patients). Only six patients had hyperkalemia without renal dysfunction. Of the patients with renal dysfunction, 66 (72%) had eGFR >30 mL/min. CONCLUSIONS:The reasons why MRA are underutilized were mainly because of contraindications. However, the data suggest that physicians are overly cautious about moderately reduced kidney function. There seems to be a 10%-18% avoidable undertreatment with MRA, especially for elderly patients that are admitted to the hospital for other reasons than heart failure. This suggests that patients with heart failure would benefit from routine follow-up at a cardiology clinic.

journal_name

Cardiovasc Ther

authors

Jonsson A,Norberg H,Bergdahl E,Lindmark K

doi

10.1111/1755-5922.12459

subject

Has Abstract

pub_date

2018-10-01 00:00:00

pages

e12459

issue

5

eissn

1755-5914

issn

1755-5922

journal_volume

36

pub_type

杂志文章
  • Impact of intensive lipid lowering on lipid profiles over time and tolerability in stable coronary artery disease: insights from a subanalysis of the coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japane

    abstract:BACKGROUND:Previous studies have demonstrated that intensive lipid lowering using rosuvastatin results in regression of coronary plaques. However, few data exist regarding lipid profiles over time, drug tolerability, and the effects of prior use of lipid lowering agents in patients on rosuvastatin treatment. Therefore,...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1111/1755-5922.12027

    authors: Kawashiri MA,Yamagishi M,Sakamoto T,Takayama T,Hiro T,Daida H,Hirayama A,Saito S,Yamaguchi T,Matsuzaki M,COSMOS Investigators.

    更新日期:2013-12-01 00:00:00

  • Noncoding RNAs as therapeutic targets in atherosclerosis with diabetes mellitus.

    abstract::Atherosclerosis is one of the major macrovascular complications of diabetes mellitus (DM), and it is the main cause of death from clinical observation. Among various cell types involved in this disorder, endothelial cells, vascular smooth muscle cells (VSMCs), and macrophages play a crucial role in the occurrence and ...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/1755-5922.12436

    authors: Tang N,Jiang S,Yang Y,Liu S,Ponnusamy M,Xin H,Yu T

    更新日期:2018-08-01 00:00:00

  • Fenoldopam in critically ill patients with early renal dysfunction. A crossover study.

    abstract:BACKGROUND:Acute kidney injury is a frequent problem among many critically ill patients, commonly in the context of multiple organ failure and decreased renal perfusion. Its presence conveys a poor prognosis. Currently, effective therapeutic interventions are limited and dopaminergic agonists have been suggested as an ...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/j.1755-5922.2010.00217.x

    authors: Cobas M,Paparcuri G,De La Pena M,Cudemus G,Barquist E,Varon A

    更新日期:2011-08-01 00:00:00

  • Influence of feeding and intracoronary dose on insulin-mediated relative akt phosphorylation in the porcine myocardium.

    abstract:AIMS:Insulin promotes Akt-dependent prosurvival signaling and reduces experimental ischemia reperfusion injury, but its clinical impact has been limited. Further understanding of the interplay between insulin and Akt in the myocardium of relevant large animal models is needed. We aimed to investigate (1) Akt phosphoryl...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1111/1755-5922.12046

    authors: Slettom G,Jonassen AK,Breivik L,Seifert R,Nordrehaug JE

    更新日期:2013-12-01 00:00:00

  • Multimodal Interventions to Enhance Adherence to Secondary Preventive Medication after Stroke: A Systematic Review and Meta-Analyses.

    abstract:INTRODUCTION:Nonadherence to secondary preventative medications after stroke is common and is associated with poor outcomes. Numerous strategies exist to promote adherence. We performed a systematic review and meta-analysis to describe the efficacy of strategies to improve adherence to stroke secondary prevention. MET...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,meta分析,评审

    doi:10.1111/1755-5922.12176

    authors: Al AlShaikh S,Quinn T,Dunn W,Walters M,Dawson J

    更新日期:2016-04-01 00:00:00

  • Clinical effectiveness and safety of antazoline-based therapy in patients with stable coronary artery disease undergoing pharmacological cardioversion of short-duration atrial fibrillation in the emergency department.

    abstract:INTRODUCTION:Options for a pharmacological cardioversion (CV) of short-duration atrial fibrillation (AF) in patients with a stable coronary artery disease (CAD) are limited to amiodarone or vernakalant. Antazoline has been reported to achieve high rates of AF conversion to sinus rhythm, but data on its effectiveness an...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1111/1755-5922.12469

    authors: Farkowski MM,Maciag A,Zurawska M,Kowalik I,Szwed H,Pytkowski M

    更新日期:2018-12-01 00:00:00

  • Comparative Lipid-Lowering/Increasing Efficacy of 7 Statins in Patients with Dyslipidemia, Cardiovascular Diseases, or Diabetes Mellitus: Systematic Review and Network Meta-Analyses of 50 Randomized Controlled Trials.

    abstract:Objective:The drug efficacy may differ among different statins, and evidence from head-to-head comparisons is sparse and inconsistent. The study is aimed at comparing the lipid-lowering/increasing effects of 7 different statins in patients with dyslipidemia, cardiovascular diseases, or diabetes mellitus by conducting s...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,meta分析

    doi:10.1155/2020/3987065

    authors: Zhang X,Xing L,Jia X,Pang X,Xiang Q,Zhao X,Ma L,Liu Z,Hu K,Wang Z,Cui Y

    更新日期:2020-04-23 00:00:00

  • Atrial fibrillation and dabigatran: has the time come to use new anticoagulants?

    abstract::Atrial fibrillation (AF) is the most common sustained cardiac rhythm disturbance found in clinical practice, increasing in prevalence with age. AF is often associated with structural heart disease, although a significant proportion has no detectable heart disease. In the last 2 decades, there has been an increase of 6...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1755-5922.2010.00216.x

    authors: Escobar C,Barrios V,Jimenez D

    更新日期:2010-10-01 00:00:00

  • The efficacy of glucocorticoids for the prevention of atrial fibrillation, or length of intensive care unite or hospital stay after cardiac surgery: a meta-analysis.

    abstract:AIMS:cardiopulmonary bypass and cardiac surgery are associated with a significant systemic inflammatory response that has been suggested playing a causative role in the development of perioperative atrial fibrillation (POAF). The goal of this meta-analysis was to determine the efficacy of glucocorticoid prophylaxis in ...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,meta分析,评审

    doi:10.1111/1755-5922.12062

    authors: Liu C,Wang J,Yiu D,Liu K

    更新日期:2014-06-01 00:00:00

  • Cell-based therapy for chronic ischemic heart disease--a clinical perspective.

    abstract::In patients with ischemic heart disease, the goal of cell therapy is to improve perfusion and function of the damaged heart muscle. For this review, we selected articles that reported the findings from the major clinical studies of cardiovascular stem cell therapy in patients with chronic ischemic heart disease. Becau...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1755-5922.2010.00214.x

    authors: Perin EC,Silva GV

    更新日期:2011-06-01 00:00:00

  • Prescribers' practice of assessing arrhythmia risk with QT-prolonging medications.

    abstract:AIMS:This study aimed to assess prescribers' monitoring for arrhythmic risk with QT-prolonging medications (LQT drugs). METHODS:Over a 6-month period, all inpatients under the care of Cardiologists (Cohort A) and General Physicians (Cohort B) at Aberdeen Royal Infirmary who were prescribed drugs with known risk of Tor...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1111/1755-5922.12085

    authors: Choo WK,Turpie D,Milne K,Davidson L,Elofuke P,Whitfield J,Broadhurst P

    更新日期:2014-10-01 00:00:00

  • What should medical practitioners know about the role of alternative medicines in cardiovascular disease management?

    abstract::Alternative medications as a term call up many different meanings, significance, and perceptions to various medical practitioners. Some are good; others are bad. A wide range of alternative medications with relevance or connection to cardiovascular (CV) disease have been considered. While many are worthless, others ha...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1755-5922.2009.00101.x

    authors: Whayne TF Jr

    更新日期:2010-04-01 00:00:00

  • A randomized study of the relative pharmacokinetics, pharmacodynamics, and safety of alirocumab, a fully human monoclonal antibody to PCSK9, after single subcutaneous administration at three different injection sites in healthy subjects.

    abstract:AIMS:We investigated the relative pharmacokinetics, pharmacodynamics, and safety of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor alirocumab following injection at three different sites. METHODS:Sixty healthy subjects (39 male, 21 female; age 20-45 years) were randomized to receive a single subcu...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/1755-5922.12093

    authors: Lunven C,Paehler T,Poitiers F,Brunet A,Rey J,Hanotin C,Sasiela WJ

    更新日期:2014-12-01 00:00:00

  • Long Noncoding RNA TUG1 Promotes the Function in ox-LDL-Treated HA-VSMCs via miR-141-3p/ROR2 Axis.

    abstract:Background:Atherosclerosis (AS) is a common severe disease around the world. The merging paper reported that long noncoding RNAs (lncRNAs) took part in diversified pathological processes of AS, although the mechanism remains unknown. This study is aimed at uncovering the profile of lncRNA taurine-upregulated gene 1 (TU...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1155/2020/6758934

    authors: Tang Y,Hu J,Zhong Z,Liu Y,Wang Y

    更新日期:2020-05-29 00:00:00

  • Metformin and its effects on myocardial dimension and left ventricular hypertrophy in normotensive patients with coronary heart disease (the MET-REMODEL study): rationale and design of the MET-REMODEL study.

    abstract::Left ventricular hypertrophy (LVH) is a common and independent risk factor for cardiovascular events in patients with coronary artery disease (CAD). Controlling blood pressure is the standard approach to the management of LVH, but this is only partially effective as LVH also persists in normotensive patients. Apart fr...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/1755-5922.12101

    authors: Mohan M,McSwiggan S,Baig F,Rutherford L,Lang CC

    更新日期:2015-02-01 00:00:00

  • Pharmacological profile of the selective mitochondrial F1F0 ATP hydrolase inhibitor BMS-199264 in myocardial ischemia.

    abstract::The mitochondrial F1F0 ATP synthase is responsible for the majority of ATP production in mammals and does this through a rotary catalytic mechanism. Studies show that the F1F0 ATP synthase can switch to an ATP hydrolase, and this occurs under conditions seen during myocardial ischemia. This ATP hydrolysis causes wasti...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1755-5922.2008.00065.x

    authors: Grover GJ,Malm J

    更新日期:2008-01-01 00:00:00

  • Impact on survival of warfarin in patients with pulmonary arterial hypertension receiving subcutaneous treprostinil.

    abstract:INTRODUCTION:Anticoagulation is a common treatment modality in patients with pulmonary arterial hypertension (PAH). Further studies are needed to appropriately assess the risk/benefit ratio of anticoagulation, particularly in PAH patients receiving PAH-specific therapies. AIMS:We use observational long-term data on PA...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1111/1755-5922.12281

    authors: Ascha M,Zhou X,Rao Y,Minai OA,Tonelli AR

    更新日期:2017-10-01 00:00:00

  • Hemodynamic Effects, Safety, and Feasibility of Intravenous Esmolol Infusion During Takotsubo Cardiomyopathy With Left Ventricular Outflow Tract Obstruction: Results From A Multicenter Registry.

    abstract:BACKGROUND:Left ventricular outflow tract obstruction (LVOTO) may complicate an episode of Takotsubo cardiomyopathy (TTC), potentially leading to cardiogenic shock. Beta-blockers are considered the most suitable treatment for such complication. AIM OF THE STUDY:The objective of this study was to evaluate the hemodynam...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1111/1755-5922.12182

    authors: Santoro F,Ieva R,Ferraretti A,Fanelli M,Musaico F,Tarantino N,Martino LD,Gennaro LD,Caldarola P,Biase MD,Brunetti ND

    更新日期:2016-06-01 00:00:00

  • Impact of Thrombocytopenia on In-Hospital Outcome in Patients Undergoing Percutaneous Coronary Intervention.

    abstract:Background:Thrombocytopenia was intuitively considered to be associated with higher risk of bleeding and multiple comorbidities after percutaneous coronary intervention (PCI). However, controversial results exist, and the real-world clinical impact of thrombocytopenia in patients undergoing PCI is largely unknown. The ...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1155/2021/8836450

    authors: Chen Z,Liu Z,Li N,Liu R,Wang M,Wang D,Li C,Li K,Luo F,He Y

    更新日期:2021-01-13 00:00:00

  • Review: Nutriceuticals as antithrombotic agents.

    abstract::Thrombus formation in a disrupted endothelium is influenced not only by the platelet redox state and reactive oxygen and nitrogen species but also by the presence of endogenous or exogenous antioxidants. Thrombus formation in the stenotic arteries is triggered predominantly by attenuated shear stress. Superoxide and n...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1755-5922.2010.00161.x

    authors: Chakrabarti S,Freedman JE

    更新日期:2010-08-01 00:00:00

  • Effects of the recombinant form of the natural human B-type natriuretic peptide and levosimendan on pulmonary hyperventilation and chemosensivity in heart failure.

    abstract:BACKGROUND:The origin of dyspnea in chronic heart failure (HF) is multifactorial, and excessive ventilation is thought to play a role in inducing this symptom. Chemosensivity is augmented in HF, correlates with increased pulmonary ventilation (VE), and is an adverse prognostic marker. Despite increased blood levels of ...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/j.1755-5922.2011.00297.x

    authors: Bocchi EA,Moura LZ,Issa VS,Cruz F,Carvalho VO,Guimarães GV

    更新日期:2013-04-01 00:00:00

  • Sulforaphane protection against the development of doxorubicin-induced chronic heart failure is associated with Nrf2 Upregulation.

    abstract:BACKGROUND:Doxorubicin (DOX) is an anthracycline antitumor drug. However, its clinical use is limited by dose-dependent cardiotoxicity and even progresses to chronic heart failure (CHF). OBJECTIVE:This study aims to investigate whether the Nrf2 activator, sulforaphane (SFN), can prevent DOX-induced CHF. METHODS:Male ...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1111/1755-5922.12277

    authors: Bai Y,Chen Q,Sun YP,Wang X,Lv L,Zhang LP,Liu JS,Zhao S,Wang XL

    更新日期:2017-10-01 00:00:00

  • miR-30c Mediates Upregulation of Cdc42 and Pak1 in Diabetic Cardiomyopathy.

    abstract:AIM:Cardiac hypertrophy and myocardial fibrosis significantly contribute to the pathogenesis of diabetic cardiomyopathy (DCM). Altered expression of several genes and their regulation by microRNAs has been reported in hypertrophied failing hearts. This study aims to examine the role of Cdc42, Pak1, and miR-30c in the p...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1111/1755-5922.12113

    authors: Raut SK,Kumar A,Singh GB,Nahar U,Sharma V,Mittal A,Sharma R,Khullar M

    更新日期:2015-06-01 00:00:00

  • The Total Incidence of Complications and the Impact of an Anticoagulation Regime on Adverse Events After Cryoballoon Ablation of Atrial Fibrillation: A Single-Center Study of 409 Patients.

    abstract:AIM:Data evaluating the complications of pulmonary vein isolation (PVI) using second-generation cryoballoons (CB) related to different anticoagulation regimes are limited. This study evaluates the total complications and the impact of novel oral anticoagulants (NOACs) compared to phenprocoumon on adverse events in the ...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1111/1755-5922.12178

    authors: Koektuerk B,Turan CH,Yorgun H,Keskin K,Schoett M,Dahmen A,Gorr E,Yang A,Hoppe C,Horlitz M,Turan RG

    更新日期:2016-06-01 00:00:00

  • Circulating CTRP1 Levels Are Increased and Associated with the STOD in Essential Hypertension in Chinese Patients.

    abstract::This study aimed to investigate the correlation between complement C1q tumor necrosis factor-related protein 1 (CTRP1) and subclinical target organ damage (STOD) in essential hypertension (EH). 720 patients were enrolled in this study, including 360 healthy subjects and 360 patients with EH. The EH group included 183 ...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1155/2019/4183781

    authors: Su Z,Tian S,Liang W

    更新日期:2019-06-02 00:00:00

  • Regenerative therapy in peripheral artery disease.

    abstract::Patients with peripheral artery disease (PAD) and critical limb ischemia are the main candidates for limb amputations and have a poor life expectancy. Frequently, these patients are not eligible for either surgical or percutaneous interventions aimed at mechanical revascularization. Therefore, new strategies need to b...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1755-5922.2009.00105.x

    authors: Germani A,Di Campli C,Pompilio G,Biglioli P,Capogrossi MC

    更新日期:2009-01-01 00:00:00

  • Effect of telmisartan on atrial fibrillation recurrences in patients with hypertension: a systematic review and meta-analysis.

    abstract:BACKGROUND:The systematic review and meta-analysis are to evaluate the effect of t Telmisartan on atrial fibrillation (AF) recurrences in hypertensive patients with paroxysmal AF. METHODS:MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials were searched. Random controlled trials (RCTs) were conduct...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,meta分析,评审

    doi:10.1111/1755-5922.12073

    authors: Pan G,Zhou X,Zhao J

    更新日期:2014-08-01 00:00:00

  • Safety and feasibility of levosimendan administration in takotsubo cardiomyopathy: a case series.

    abstract:BACKGROUND:Levosimendan is a noncatecholamine inotrope that does not increase oxygen consumption, utilized for the treatment for acute heart failure with left ventricular (LV) systolic dysfunction. Its use in takotsubo cardiomyopathy (TTC), a disease that contraindicates the use of catecholamine inotropes, is not well ...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1111/1755-5922.12047

    authors: Santoro F,Ieva R,Ferraretti A,Ienco V,Carpagnano G,Lodispoto M,Di Biase L,Di Biase M,Brunetti ND

    更新日期:2013-12-01 00:00:00

  • Cytochrome P450 2C9 gene polymorphism and warfarin maintenance dosage in pediatric patients: A systematic review and meta-analysis.

    abstract:AIM:To assess the effect of Cytochrome P450 2C9 (CYP2C9) gene polymorphism on pediatric warfarin maintenance dosage requirement. METHODS:A previously developed search strategy was conducted in PubMed, EMBASE, and the Cochrane Library. Eligible studies published prior to January 27, 2016, were identified and compared a...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,meta分析,评审

    doi:10.1111/1755-5922.12230

    authors: Zhang J,Tian L,Huang J,Huang S,Chai T,Shen J

    更新日期:2017-02-01 00:00:00

  • Iron deficiency in heart failure: Efficacy and safety of intravenous iron therapy.

    abstract:AIM:To discuss the pathophysiology of iron metabolism in chronic heart failure (CHF) and the current knowledge of the efficacy of intravenous (IV) iron therapy in patients with CHF and identify points of controversy as well as highlight areas for future research. DISCUSSION:Iron deficiency is a recognized complication...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/1755-5922.12301

    authors: Kang CK,Pope M,Lang CC,Kalra PR

    更新日期:2017-12-01 00:00:00